147 related articles for article (PubMed ID: 19961222)
1. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
[TBL] [Abstract][Full Text] [Related]
2. Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Ginman N; Johansson A; Wallberg H; Larhed M; Samuelsson B; Unge T; Hallberg A
J Med Chem; 2006 Mar; 49(5):1828-32. PubMed ID: 16509598
[TBL] [Abstract][Full Text] [Related]
3. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
[TBL] [Abstract][Full Text] [Related]
4. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
Wu X; Ohrngren P; Ekegren JK; Unge J; Unge T; Wallberg H; Samuelsson B; Hallberg A; Larhed M
J Med Chem; 2008 Feb; 51(4):1053-7. PubMed ID: 18215014
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
De Rosa M; Unge J; Motwani HV; Rosenquist Å; Vrang L; Wallberg H; Larhed M
J Med Chem; 2014 Aug; 57(15):6444-57. PubMed ID: 25054811
[TBL] [Abstract][Full Text] [Related]
6. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
[TBL] [Abstract][Full Text] [Related]
8. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
9. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F
Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613
[TBL] [Abstract][Full Text] [Related]
11. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
14. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
Joshi A; Véron JB; Unge J; Rosenquist Å; Wallberg H; Samuelsson B; Hallberg A; Larhed M
J Med Chem; 2013 Nov; 56(22):8999-9007. PubMed ID: 24160253
[TBL] [Abstract][Full Text] [Related]
17. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
[TBL] [Abstract][Full Text] [Related]
18. Variations of the P2 group in HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Gising J; Wallberg H; Larhed M; Samuelsson B; Hallberg A
Org Biomol Chem; 2006 Aug; 4(16):3040-3. PubMed ID: 16886068
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
20. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
